A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600E/K mutant advanced melanoma

被引：17

作者：

Algazi, Alain Patrick ^{[1
]}

Rotow, Julia ^{[1
]}

Posch, Christian ^{[2
,3
]}

Ortiz-Urda, Susana ^{[4
]}

Algazi, Alain Patrick ^{[1
]}

Munster, Pamela N. ^{[1
]}

Daud, Adil ^{[1
]}

机构：

[1] UCSF Hematol & Oncol, San Francisco, CA USA

[2] Tech Univ Munich, Dept Dermatol & Allergy, Munich, Germany

[3] Sigmund Freud Univ, Sch Med, Vienna, Austria

[4] UCSF Dermatol, San Francisco, CA USA

来源：

PIGMENT CELL & MELANOMA RESEARCH | 2019年 / 32卷 / 04期

关键词：

DOSE-ESCALATION; PHASE-I; TRAMETINIB; PI3K; PTEN; NRAS;

D O I：

10.1111/pcmr.12777

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：603 / 606

页数：4

共 12 条

[1] Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma [J].

Algazi, Alain P. ;

Esteve-Puig, Rosaura ;

Nosrati, Adi ;

Hinds, Brian ;

Hobbs-Muthukumar, Adele ;

Nandoskar, Prachi ;

Ortiz-Urda, Susana ;

Chapman, Paul B. ;

Daud, Adil .

PIGMENT CELL & MELANOMA RESEARCH, 2018, 31 (01) :110-114

[2] A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors [J].

Bedard, Philippe L. ;

Tabernero, Josep ;

Janku, Filip ;

Wainberg, Zev A. ;

Paz-Ares, Luis ;

Vansteenkiste, Johan ;

Van Cutsem, Eric ;

Perez-Garcia, Jose ;

Stathis, Anastasios ;

Britten, Carolyn D. ;

Le, Ngocdiep ;

Carter, Kirsten ;

Demanse, David ;

Csonka, Denes ;

Peters, Malte ;

Zubel, Angela ;

Nauwelaerts, Heidi ;

Sessa, Cristiana .

CLINICAL CANCER RESEARCH, 2015, 21 (04) :730-738

[3] Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors [J].

Bendell, Johanna C. ;

Rodon, Jordi ;

Burris, Howard A. ;

de Jonge, Maja ;

Verweij, Jaap ;

Birle, Diana ;

Demanse, David ;

De Buck, Stefan S. ;

Ru, Qinhua C. ;

Peters, Malte ;

Goldbrunner, Michael ;

Baselga, Jose .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (03) :282-290

[4] BrafV600E cooperates with Pten loss to induce metastatic melanoma [J].

Dankort, David ;

Curley, David P. ;

Cartlidge, Robert A. ;

Nelson, Betsy ;

Karnezis, Anthony N. ;

Damsky, William E., Jr. ;

You, Mingjian J. ;

DePinho, Ronald A. ;

McMahon, Martin ;

Bosenberg, Marcus .

NATURE GENETICS, 2009, 41 (05) :544-552

[5] PI3K and cancer: lessons, challenges and opportunities [J].

Fruman, David A. ;

Rommel, Christian .

NATURE REVIEWS DRUG DISCOVERY, 2014, 13 (02) :140-156

[6] Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma [J].

Goel, Vikas K. ;

Lazar, Alexander J. F. ;

Warneke, Carla L. ;

Redston, Mark S. ;

Haluska, Frank G. .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2006, 126 (01) :154-160

[7] A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma [J].

Grippo, J. F. ;

Zhang, W. ;

Heinzmann, D. ;

Yang, K. H. ;

Wong, J. ;

Joe, A. K. ;

Munster, P. ;

Sarapa, N. ;

Daud, A. .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (01) :103-111

[8] RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth [J].

Hatzivassiliou, Georgia ;

Song, Kyung ;

Yen, Ivana ;

Brandhuber, Barbara J. ;

Anderson, Daniel J. ;

Alvarado, Ryan ;

Ludlam, Mary J. C. ;

Stokoe, David ;

Gloor, Susan L. ;

Vigers, Guy ;

Morales, Tony ;

Aliagas, Ignacio ;

Liu, Bonnie ;

Sideris, Steve ;

Hoeflich, Klaus P. ;

Jaiswal, Bijay S. ;

Seshagiri, Somasekar ;

Koeppen, Hartmut ;

Belvin, Marcia ;

Friedman, Lori S. ;

Malek, Shiva .

NATURE, 2010, 464 (7287) :431-U132

[9] Navigating the Therapeutic Complexity of PI3K Pathway Inhibition in Melanoma [J].

Kwong, Lawrence N. ;

Davies, Michael A. .

CLINICAL CANCER RESEARCH, 2013, 19 (19) :5310-5319

[10] Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial [J].

Long, Georgina V. ;

Stroyakovskiy, Daniil ;

Gogas, Helen ;

Levchenko, Evgeny ;

de Braud, Filippo ;

Larkin, James ;

Garbe, Claus ;

Jouary, Thomas ;

Hauschild, Axel ;

Grob, Jean-Jacques ;

Chiarion-Sileni, Vanna ;

Lebbe, Celeste ;

Mandala, Mario ;

Millward, Michael ;

Arance, Ana ;

Bondarenko, Igor ;

Haanen, John B. A. G. ;

Hansson, Johan ;

Utikal, Jochen ;

Ferraresi, Virginia ;

Kovalenko, Nadezhda ;

Mohr, Peter ;

Probachai, Volodymr ;

Schadendorf, Dirk ;

Nathan, Paul ;

Robert, Caroline ;

Ribas, Antoni ;

DeMarini, Douglas J. ;

Irani, Jhangir G. ;

Swann, Suzanne ;

Legos, Jeffrey J. ;

Jin, Fan ;

Mookerjee, Bijoyesh ;

Flaherty, Keith .

LANCET, 2015, 386 (9992) :444-451

← 1 2 →